問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Cardinal Tien Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間：2023-09-19

馬文雅
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

馬文雅

Cardinal Tien Hospital

Division of Endocrinology

List

28Cases

2014-06-01 - 2016-08-31

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

  • Condition/Disease

    Treatment of Type 2 Diabetes Mellitus (T2DM)

  • Test Drug

    Ertugliflozin

Participate Sites
5Sites

Terminated5Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2014-07-31 - 2014-09-30

Phase III

An open-label, randomized, multi-center, parallel grouped clinical trial comparing the efficacy and safety of Mylan's Insulin Glargine and Lantus® for patients with type 2 diabetes.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Mylan′s Insulin Glargine

Participate Sites
7Sites

Terminated7Sites

2014-11-11 - 2018-11-26

Phase III

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

  • Condition/Disease

    Type II Diabetes

  • Test Drug

    Canagliflozin

Participate Sites
8Sites

Terminated8Sites

2012-02-01 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-11-12 - 2018-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events

  • Condition/Disease

    Type 2 Diabete

  • Test Drug

    TAK-875

Participate Sites
7Sites

Terminated7Sites

2010-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-08-01 - 2014-01-31

Phase III

LY2189265 compares with insulin Glargine and the combined use of insulin Lispro on the treatment to target of type 2 diabetes (AWARD-4: Evaluation of the weekly use of LY2189265 in patients with type 2 diabetes. 4 [Assessment of Weekly AdministRation of LY2189265 in Diabetes-4]

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2189265

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2009-07-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-01-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB